Results 181 to 190 of about 19,375 (263)

A Generalized NMF-Based Method for Analyzing Time-Resolved Spectroscopic Data. [PDF]

J Phys Chem A
Kobeleva E, Chewle S, Horch M, Weber M.
europepmc   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1195-1207, July 2026.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

Gut microbiome composition and strain-sharing in multiplex autism spectrum disorder families. [PDF]

Nat Commun
Lu W, Wong OWH, Zhu J, Chen S, Tun HM, Wan Y, Xu Z, Cheung CP, Ching JYL, Cheong PK, Chan S, Wong S, Chan D, Chan FKL, Su Q, Ng SC.   +15 more
europepmc   +1 more source

European S2k guidelines on management of autoimmune blistering diseases in children and adolescents

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 7, Page 1137-1161, July 2026.
Autoimmune blistering disorders (AIBDs) in children are rare, challenging to diagnose and treat and often require immunosuppressants. Until now, no paediatric care guidelines existed. The EADV Task Force for AIBDs has developed the consensus‐based recommendations, enabling physicians to adopt a uniform, tailored treatment strategy to improve outcomes ...
A. Nanda, B. Tedbirt, C. Bodemer, M. C. Bolling, M. El Hachem, M. Nikolić, E. Benton, M. Caproni, D. De, D. Didona, K. Drenovska, M. Goebeler, M. Hertl, B. Horváth, M. Kasperkiewicz, D. Kiritsi, M. Larralde, A. V. Marzano, J. Meijer, D. F. Murrell, J. Powell, E. Sprecher, N. S. Chandran, M. M. Tomayko, S. Uzun, N. van Beek, H. Ott, A. Patsatsi, A. Torrelo, A. Welfringer‐Morin, E. Schmidt, P. Joly   +31 more
wiley   +1 more source

Risk of skin and subcutaneous diseases in paediatric HIV-exposed uninfected individuals in the United States. [PDF]

Br J Dermatol
El Banna G, Wishner S, Baker N, Peacker BL, Braun N, Ma KS, Chen ST, Bebell LM.   +7 more
europepmc   +1 more source

Hylacross Hyaluronic Acid Injectables in the Lips: Global Expert Perspectives for Achieving Optimal Esthetic Outcomes

Journal of Cosmetic Dermatology, Volume 25, Issue 7, July 2026.
ABSTRACT Background Lips are a common area of concern for patients seeking facial esthetic treatment. Hyaluronic acid (HA) injectables are the gold standard for nonsurgical lip improvement, and the Hylacross products may be particularly well suited to this area.
Sarah G. Boxley, Kathleen M. Morno, Lina María Cadena Ortiz, William McGillivray, Hani Aljohani, Dario Bertossi, Carola de la Guardia   +6 more
wiley   +1 more source

Early-Onset Herpes Zoster in a 10-Month-Old Infant Following Nonvenomous Snake Exposure: A Rare Case Report. [PDF]

Clin Case Rep
Hoseini SM, Saghafi M, Saghafi F.
europepmc   +1 more source

Meeting Report From the 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting, Amsterdam, the Netherlands, October 2025

Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.
ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin, Katherina Alsina, Allison S. Betof, Joseph Birkett, Marcus O. Butler, George Cole Jr., Rizwan Haq, Florian A. Karreth, Vinit B. Mahajan, Rahul Marpadga, Prithvi Mruthyunjaya, Paul Nathan, Jonas A. Nilsson, Gary Palmer, Joseph J. Sacco, Takami Sato, Sarah Stanhope, Pang‐ning Teng, Kyleigh LiPira   +18 more
wiley   +1 more source

Incidence of AIDS-Defining Illness by Cancer Status in an Observational Study Among Medicaid Beneficiaries Living With HIV in the United States, 2001-2015. [PDF]

J Acquir Immune Defic Syndr
Zhou Y, Lau B, Rudolph JE, Zhang X, Xu X, Yenokyan K, Wentz EL, Calkins KL, Joshu CE.   +8 more
europepmc   +1 more source

Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 24: Suitability of taxonomic units notified to EFSA until March 2026

EFSA Journal, Volume 24, Issue 7, July 2026.
Abstract The Qualified Presumption of Safety (QPS) process was developed to provide a harmonised safety assessment approach to support EFSA Scientific Panels and Units. The QPS approach assesses the taxonomic identity, body of knowledge and safety of microorganisms intentionally added to the food and feed chain.
EFSA Panel on Biological Hazards (BIOHAZ), Ana Allende, Avelino Alvarez‐Ordóñez, Valeria Bortolaia, Sara Bover‐Cid, Alessandra De Cesare, Wietske Dohmen, Laurent Guillier, Liesbeth Jacxsens, Maarten Nauta, Lapo Mughini‐Gras, Jakob Ottoson, Luisa Peixe, Fernando Perez‐Rodriguez, Panagiotis Skandamis, Elisabetta Suffredini, Marianne Chemaly, Pier Sandro Cocconcelli, Pablo Salvador Fernández Escámez, Miguel Prieto Maradona, Amparo Querol, Lolke Sijtsma, Ingvar Sundh, Fulvio Barizzone, Marta Bisaschi, Sandra Correia, Lieve Herman   +26 more
wiley   +1 more source